Pharmacotherapy Strategies for Opioid Use Disorder

"XR-NTX has been evaluated and earned a safety rating of 2, as its efficacy is still being explored in Phase 2 trials."

"XR-NTX is a medication typically used to reduce physical activity, but can also provide relief from opioid dependency, illness and ache."

"XR-NTX was first researched in 2007 at Columbia Addiction Services and Psychotherapy Intervention Research. This drug has a total of 515 completed clinical trials on record, 94 of which are still active primarily based out Orlando, Florida."

"Patients across the country can join this study at 24 different clinical sites, such as Aspire Health Partners in Orlando, Florida; Tarzana Treatment Centers Integrated Health Care in Tarzana, California; and Gateway Community Services in Jacksonville, New hampshire."

"As per data on clinicaltrials.gov, this study is now accepting applicants for participation. The trial was first published in June 2021 and the page was last updated in September 2022."

"As reported by the trial's sponsor, The Emmes Company, LLC ,the primary outcome measure to be assessed over a 24-week interval is continuous retention in MOUD treatment. Secondary outcomes that will also be observed include weekly opioid abstinence (as recorded via Timeline Followback and backed up with toxicology results), other discontinuation outcomes such as those who did not meet criteria for the primary outcome but relapsed or discontinued without relapse after restarting medication within 24 weeks of discontinuing it, and finally an assessment of patients' progress through 4 domains at week 24 using the Treatment Effectiveness Assessment (TEA)."

"This study necessitates the inclusion of 2630 participants that meet predetermined criteria. These individuals may come from sites such as Aspire Health Partners in Orlando, Florida and Tarzana Treatment Centers Integrated Health Care in Tarzana, California."